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Background and Aims: The insulin action profiles of subcutaneously injected 
short acting insulin analogues are still slow compared to physiologically released 
human insulin.  Thus postprandial glucose excursions cannot be avoided. InsuPad is 
a medical device designed  to accelerate insulin delivery rate  by applying local heat 
at the insulin injection site. Whenever an insulin injection is given, the skin surface 
temperature is heated up locally to 38.5 C° for 30 minutes. This pilot-study examines 
the impact of the InsuPad use on postprandial glucose excursion after breakfast and 
dinner in daily life conditions.
Methods: Diabetic patients with high insulin resistance were instructed to use the 
InsuPad when injecting insulin bolus prior to breakfast and dinner in one study phase 
for one month  and to measure their blood glucose at least five times per day (pre- and 
post-breakfast, pre-lunch and pre- and post-dinner). In the other study phase patients 
were instructed to maintain the same blood glucose measurement schedule for one 
month without using the InsuPad device. The order of the phases was randomized. 
All blood glucose data were transmitted to a central computer using the DIASEND 
System. A valid pre-post-prandial measurement time difference was 75 - 135 minutes. 
An ANOVA, controlling for order of study phase, patient and meal (breakfast vs. dinner) 
was used to analyse the effect of the InsuPad on postprandial glucose excursions. 10 
diabetic patients were using short acting insulin analogues. Participants had considerable 
overweight and were rather insulin resistant. Two thirds of the sample were type 2 
diabetic patients, receiving oral anti-diabetic medication in addition to a multiple daily 
injection insulin therapy (see table 1).
Results: In the two 4 week periods there were 283 vs. 257 valid pre-post-measurements 
with and without using the InsuPad after breakfast and dinner. Also the time differences, 
mean carbohydrate intake and insulin doses between pre-meal and postprandial glucose 
values were very similar in the study phases with and without InsuPad (see table 2). 
Preprandial blood glucose levels were similar before breakfast and dinner in both phases 
and decreased by 0.05 ± 59.1 mg/dl if InsuPad was used, whereas the postprandial 
glucose levels significantly increased by 11.3 ± 56.3 mg/dl if the InsuPad was not used 
(see figure 1). After breakfast the InsuPad was able to reduce the pre-post-prandial blood 
glucose difference by 9 mg/dl (see figure 2), whereas after dinner the pre-post-prandial 
difference was significantly reduced by 15 mg/dl (see figure 3). The overall glycaemic 
control (mean total blood glucose values) was significantly better when using the InsuPad 
compared to the no-use-phase (149.7 ± 54.5 mg/dl vs. 158.7 ± 57.7 mg/dl; p=.016; 
see figure 4).  Percentage of hypoglycaemic (< 60 mg/dl) or hyperglycaemic (> 300 mg/
dl) blood glucose measurements were slightly decreased when using the InsuPad but the 
difference was not statistically significant (% hypoglycaemic  values 1.5% vs. 1.8%, p=.496; 
% hyperglycaemic values 1.6% vs. 2.1%, p=.250). Also the numbers of biochemically 
defined hypoglycaemic or hyperglycaemic episodes per week were not substantially 
different during the phases with and without InsuPad use (see figure 5 and 6).
Conclusion:  This pilot-study indicates that local heating of the insulin injection site 
by use of the InsuPad is able to reduce postprandial blood glucose excursions as well 
as mean glucose values significantly in daily life in diabetic patients with a high insulin 
resistance. Safety parameters like the prevalence of hypoglycaemic and hyperglycaemic 
glucose measurements were not affected by the use of InsuPad.
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